NCT00000743View on ClinicalTrials.gov

A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

Not specified

Study Completion Date

May 31, 1995

Conditions
HIV Infections
Interventions
DRUG

Alvircept sudotox

DRUG

Zidovudine

Trial Locations (4)

21287

Johns Hopkins Adult AIDS CRS, Baltimore

90095

UCLA CARE Center CRS, Los Angeles

275997215

Unc Aids Crs, Chapel Hill

701122699

Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU, New Orleans

Sponsors

Collaborators (2)

Upjohn
Glaxo Wellcome
All Listed Sponsors
collaborator

Upjohn

INDUSTRY

collaborator

Glaxo Wellcome

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH